Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashur

Showing results (201-210 of 234) with videos related to

Pageof 24
Sort By:
Pacing and Clinical Electrophysiology : PACE|July 31, 2025
Use of Direct Oral Anticoagulants Following Cardiac Implantable Electronic Device PlacementCarmel Ashur, Li Qin, Karl E Minges, et al.
Cancer Letters|November 22, 2020
DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancerDotan Moskovich, Adi Alfandari, Yael Finkelshtein, et al.
Oncotargets and Therapy|September 27, 2014
Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesisPaul J Davis, Hung-Yun Lin, Thangirala Sudha, et al.
Oncogene|September 24, 2021
Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatmentDotan Moskovich, Yael Finkelshtein, Adi Alfandari, et al.
Oncogene|March 16, 2023
Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatmentDotan Moskovich, Yael Finkelshtein, Adi Alfandari, et al.
The Journal of Infectious Diseases|August 19, 2000
ReplyFrey, Dagan, Ashur, et al.
Tropical Medicine and Health|March 28, 2013
The NUITM-KEMRI P3 Laboratory in Kenya: Establishment, Features, Operation and MaintenanceShingo Inoue, Ernest Wandera, Gabriel Miringu, et al.
Cancer Letters|April 27, 2023
Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233]Dotan Moskovich, Adi Alfandari, Yael Finkelshtein, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 2, 2022
Right atrial structural remodeling predict worse outcomes in transcatheter mitral valve repairMatthew S Miller, Jamey Cutts, Marissa Donatelle, et al.
Annals of the New York Academy of Sciences|December 26, 1996
Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clockI Gozes, G Lilling, A Davidson, et al.
Pageof 24

Showing results (201-210 of 234) with videos related to

Sort By:
Pageof 24
Pacing and Clinical Electrophysiology : PACE|July 31, 2025
Use of Direct Oral Anticoagulants Following Cardiac Implantable Electronic Device PlacementCarmel Ashur, Li Qin, Karl E Minges, et al.
Cancer Letters|November 22, 2020
DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancerDotan Moskovich, Adi Alfandari, Yael Finkelshtein, et al.
Oncotargets and Therapy|September 27, 2014
Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesisPaul J Davis, Hung-Yun Lin, Thangirala Sudha, et al.
Oncogene|September 24, 2021
Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatmentDotan Moskovich, Yael Finkelshtein, Adi Alfandari, et al.
Oncogene|March 16, 2023
Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatmentDotan Moskovich, Yael Finkelshtein, Adi Alfandari, et al.
The Journal of Infectious Diseases|August 19, 2000
ReplyFrey, Dagan, Ashur, et al.
Tropical Medicine and Health|March 28, 2013
The NUITM-KEMRI P3 Laboratory in Kenya: Establishment, Features, Operation and MaintenanceShingo Inoue, Ernest Wandera, Gabriel Miringu, et al.
Cancer Letters|April 27, 2023
Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233]Dotan Moskovich, Adi Alfandari, Yael Finkelshtein, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 2, 2022
Right atrial structural remodeling predict worse outcomes in transcatheter mitral valve repairMatthew S Miller, Jamey Cutts, Marissa Donatelle, et al.
Annals of the New York Academy of Sciences|December 26, 1996
Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clockI Gozes, G Lilling, A Davidson, et al.
Pageof 24